Cytopaenia Clinical Trial
Official title:
A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
| Verified date | January 2019 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This was a non-randomized, open-label, phase II study to assess the efficacy and safety of
eltrombopag in Japanese moderate or more severe aplastic anemia (AA) subjects with a platelet
count <30,000/microliter who were refractory to anti-thymocyte globulin (ATG)-based
immunosuppressive therapy (IST), who have relapsed after ATG-based IST, or who are ineligible
for ATG-based IST.
Eltrombopag was expected to improve trilineage blood cells and decrease transfusion frequency
based on the result from the previous study in patients with severe AA. This study used the
hematologic response rate, defined as the proportion of subjects showing improvement in at
least one of the three blood cell lineages or a decrease in blood transfusion volume, as the
primary endpoint.
A total of 36 subjects were screened and 21 were enrolled in the study. Treatment with
eltrombopag started at 25 milligram (mg)/day and increased by 25 mg/day every 2 weeks
according to the platelet count up to 100 mg/day. Response assessment was performed at 3
months after starting the study treatment (Week 13). Subjects in whom the treatment was
assessed as effective continued with the study treatment. Subjects in whom the treatment was
assessed as effective (when meeting any of the response criteria) at 6 months after starting
the study treatment (Week 26) might enter the extension phase and continue the treatment with
eltrombopag. The primary endpoint was the hematologic response rate at Week26.
| Status | Completed |
| Enrollment | 21 |
| Est. completion date | September 5, 2017 |
| Est. primary completion date | September 10, 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 79 Years |
| Eligibility |
Key Inclusion Criteria: - Subject has given written informed consent. If a subject is under 20 years, both the subject and the subject's legally acceptable representative have to give informed consent. - Japanese subjects aged >=18 and <80 years at the time of informed consent. - Diagnosis of moderate (stage II) or more Aplastic Anemia (AA) with platelet count <30,000/microliter (based on the diagnosis criteria of AA established by the Study Group on Idiopathic Hematopoietic Disorder as a part of Research on Measures for Intractable Diseases supported by Health and Labor Science Research Grants). - Subjects who became refractory to Anti-thymocyte globulin (ATG)-based Immunosuppressive therapy (IST), who have relapsed after ATG-based IST, or who are ineligible for ATG-based IST. Note: Refractory or relapsed subjects to whom re-treatment with ATG is indicated should not be enrolled in the study. Subjects who have a sibling donor with matched human leukocyte antigen (HLA) should not be enrolled in the study. However, such subjects may be enrolled if the disease relapsed after hematopoietic stem cell transplantation (HSCT), if HSCT is not indicated, or the subject does not want to undergo HSCT. - Adequate organ function at screening and Day 1 as defined as follows: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3 × central laboratory upper limit of normal (ULN); Creatinine, total bilirubin, and alkaline phosphatase (ALP) <1.5 × central laboratory ULN (total bilirubin <2.5 × central laboratory ULN with Gilbert's Syndrome) - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 or 1 - Subjects with QT interval corrected for heart rate by Fridericia's formula (QTcF) <450 milliseconds (msec) or QTcF<480 msec with branch block. Corrected QT interval duration (QTc) is QT interval corrected by Fridericia formula (QTcF), machine or manual over read. QTcF is based on single or averaged QTc value of triplicate electrocardiogram (ECG). - Subjects who meet one of the following conditions: Male subjects who have a female partner of childbearing potential must either have a prior vasectomy or agree to use an acceptable contraception from time of enrollment in the study until 16 weeks after the last dose of eltrombopag (based upon the lifecycle of sperm); Female subjects of non-childbearing potential (who are physiologically unable to become pregnant) defined as: Premenopausal women with documented bilateral oophorectomy, bilateral tubal ligation, or hysterectomy; or postmenopausal women after at least 12 months of natural amenorrhea [if uncertain, postmenopausal state should be confirmed by hematology result of follicle stimulating hormone (FSH) >40 milli international unit /milliliter (mIU/mL) or estradiol <40 picogram (pg)/mL (<140 picomole /Liter (pmole/L)].; Female subjects of childbearing potential: Defined as those not meeting the definition of non-childbearing potential. Female subjects of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) or urine pregnancy test within 7 days prior to the first dose of study treatment. It is recommended that the pregnancy test should be performed as close as possible to the first dose of study treatment. Female subjects with a positive pregnancy test must be excluded from the study. Subjects with a negative pregnancy test must use acceptable contraception including abstinence after the pregnancy test. Subjects must agree to use the acceptable contraception including abstinence from 14 days prior to the first dose of study treatment until 28 days after the last dose of eltrombopag. Key Exclusion Criteria: - Treatment with ATG in the past 12 months. Note: Subjects who are receiving cyclosporine or anabolic steroids (excluding danazol) at a stable dose may be enrolled if laboratory values are stable at screening. - Congenital aplastic anemia (e.g., Fanconi anemia, congenital dyskeratosis) - Paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size determined by flow cytometry >=50% - Presence of chromosomal aberration (-7/7q- detected by fluorescence in situ hybridization (FISH), or other aberrations detected by Giemsa (G)-band staining) Note: Subjects with the result by G-band staining (bone marrow aspiration) not adopted into the abnormal clone definition of An International System for Human Cytogenetic Nomenclature (ISCN) can be enrolled as no chromosomal aberration. - Past history of thromboembolism or current use of anticoagulants. Note: Subjects with antiphospholipid antibody syndrome (APS) should not be enrolled. - Past or current history of malignant tumor. Note: Subjects who have a history of completely resected malignant tumor and have been disease-free for 5 years are eligible. - Subjects who test positive for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody at screening. Note: Subjects with inactive hepatitis B may be enrolled. Judgment of inactive hepatitis B will be done by the medical advisor. - Subjects with concurrent uncontrollable severe infection (e.g., sepsis) - Hepatic cirrhosis - Cardiac disorder (congestive heart disease of New York Heart Association (NYHA) functional classification Grade II/III/IV), or arrhythmia with a risk of thrombosis (e.g., atrial fibrillation). Note: Subjects with NYHA Grade II due to cardiac disorder should not be enrolled but those with NYHA Grade II due to Aplastic Anemia (AA) may be enrolled. - Alcohol or drug abuse - Pregnant women (a positive serum or urine pregnancy test within 7 days prior to the first dose of study treatment) or lactating women. Note: Female subjects who are lactating are eligible to participate if they discontinue nursing prior to the first dose of study treatment and refrain from nursing until 5 days after the treatment completion. - Past history of immediate or delayed hypersensitivity to compounds chemically similar to eltrombopag or their activators - Treatment with another investigational product within 30 days or the period 5-fold longer than the half-life of the investigational product, whichever longer, prior to the first dose of eltrombopag - Prior treatment with eltrombopag, romiplostim, or any other Thrombopoietin (TPO) receptor agonist - Use of prohibited concomitant medications. |
| Country | Name | City | State |
|---|---|---|---|
| Japan | Novartis Investigative Site | Aichi | |
| Japan | Novartis Investigative Site | Aichi | |
| Japan | Novartis Investigative Site | Hyogo | |
| Japan | Novartis Investigative Site | Ibaraki | |
| Japan | Novartis Investigative Site | Ishikawa | |
| Japan | Novartis Investigative Site | Miyagi | |
| Japan | Novartis Investigative Site | Okayama | |
| Japan | Novartis Investigative Site | Osaka | |
| Japan | Novartis Investigative Site | Osaka | |
| Japan | Novartis Investigative Site | Osaka | |
| Japan | Novartis Investigative Site | Tochigi | |
| Japan | Novartis Investigative Site | Tokyo |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Hematological Response at Week 26 | Hematologic response rate at 6 months (at WeeK 26) after the start of study treatment was defined as the percentage of subjects who met any of the response criteria (Platelet count, Hemoglobin level, Neutrophil count). 1 ) Platelet count: an increase from baseline by 20,000/µL or more (In the absence of platelet transfusion), or no platelet transfusion requirements for 8 weeks; 2) Hemoglobin: When the baseline hemoglobin level is <9 g/dL: Without RBC transfusion at baseline, an increase from baseline by 1.5 g/dL or more; With RBC transfusion at baseline, a decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period compared to the pre-treatment 8-week period (1 unit = RBC derived from 200 mL blood); 3) Neutrophil count: an increase from baseline by 500/µL or more (in the absence of granulocyte colony-stimulating factor (G-CSF)), or (if < 500/µL at baseline) an increase by 100 % or more. Only descriptive analysis done. | D183 (Week 26) | |
| Secondary | Change in Platelet Count From Baseline in the Absence of Platelet Transfusion Over Time | The changes in observed values for Platelet Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. | Up to 2.5 years | |
| Secondary | Change in Hemoglobin From Baseline in the Absence of Red Blood Cell (RBC) Transfusion Over Time | The changes in observed values for Hemoglobin were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. | Up to 2.5 years | |
| Secondary | Change in Neutrophil Count From Baseline in the Absence of Granulocyte-colony Stimulating Factor (G-CSF) Over Time | The changes in observed values for Neutrophil Count were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. | Up to 2.5 years | |
| Secondary | Hematological Response at Week 13 in Terms of the Platelet Count, Hemoglobin Level and Neutrophil Count | The frequency and percentage were calculated with 95% confidence interval (CI) of responses (which meet each response criteria) of platelet count, hemoglobin and neutrophil count at Week 13. | Week 13 | |
| Secondary | Duration of Hematological Response in Participants Who Responded at the Week 13 | The duration of haematological response was defined, for subjects who responded at the Week 13 visit, as the number of months from the first date of a response until the first date of a relapse or the date the subject was last assessed. Only subjects with at least 2 response assessments were included in the duration of response assessment. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. | Up to 2.5 years | |
| Secondary | Volume of (Platelet and RBC) Transfusion in Each Period | The amount of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. | Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52 | |
| Secondary | Frequency of (Platelet and RBC) Transfusion in Each Period | The frequency of blood transfusion (platelets, RBC) were summarized. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. | Day 1, Day 92 (Week 13), Day 183 (Week 26), Extension W39 and Extension W52 | |
| Secondary | Percentage of Participants With Reduced Volume of Transfusion (Platelet and RBC) | The proportion of the participants for whom the amount of blood transfusion (platelets and RBC) is decreased was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent. | Up to 2.5 years | |
| Secondary | Percentage of Participants Who Become Transfusion (Platelet and RBC) Independent | The proportion of participants for whom blood transfusion (platelets and RBC) became unnecessary was measured and reported as a percentage. The measurements were followed up to Week 26 and thereafter in the extension part (Up to the launch of the product after approval, which will be approximately up to two and a half years). Only descriptive analysis done. This analysis was performed for the subjects who were baseline transfusion dependent. | Up to 2.5 years | |
| Secondary | Long-term Safety and Tolerability of Eltrombopag | The frequency and percentage of subjects who experienced adverse events (AEs), serious adverse events (SAEs) and deaths by primary system organ class (SOC) and MedDRA preferred term were summarized. | Up to 30 days after last dose of study treatment | |
| Secondary | Number of Participants With Bleeding Events and Severity of Bleeding | The measurements were followed up to Week 26 and thereafter in the extension part. | Up to 30 days after last dose of study treatment | |
| Secondary | Maximum Observed Plasma Concentration (Cmax) for Eltrombopag | At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods. | Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose) | |
| Secondary | Time to Reach the Maximum Plasma Concentration (Tmax) for Eltrombopag | At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods. | Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose) | |
| Secondary | Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Subject Across All Treatments (AUC 0-t) and Over the Dosing Interval (AUC 0-tau) for Eltrombopag | At some study sites, full blood sampling for pharmacokinetic (PK) evaluation of Eltrombopag was performed on Day 14 to calculate Cmax, tmax, AUC(0-t), and AUC(0-tau). PK parameters were calculated from plasma concentration-time data using non-compartmental methods. | Day 14 at 25 mg QD (-0.05, 0.15, 0.30, 0.45, 1.00, 1.30 and 24.00), at 50,75 and 100 mg QD (pre-dose) | |
| Secondary | Mean Change in Eltrombopag Concentration in Pharmacokinetic Serum Samples Over Time at Days 14 and 15 | At every study center, blood samples was be collected on Day 15 of multiple doses of eltrombopag 25 mg to determine the plasma eltrombopag concentration prior to the next dose (trough concentration). In addition, one-point pre-dose blood sampling was performed at every study center on Day 15 of multiple doses of eltrombopag 50 mg, 75 mg and 100 mg to determine trough concentrations. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. | Day 14 (pre-dose, 1, 2, 4, 6, 8 and 24 post-dose), Day 15 (pre-dose) |